Clinical Trial Update: Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for patients with resectable or borderline resectable pancreatic ductal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Emory University | Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma | Phase 2 | Status: RECRUITING